Last reviewed · How we verify
Pembrolizumab and Chemotherapy drugs
Pembrolizumab and Chemotherapy drugs is a PD-1 inhibitor (in combination with chemotherapy) Small molecule drug developed by University Hospital, Brest. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer (NSCLC), Triple-negative breast cancer, Gastric or gastroesophageal junction cancer.
Pembrolizumab blocks PD-1 to restore anti-tumor immunity, while chemotherapy drugs kill cancer cells directly; together they enhance immune activation against residual disease.
Pembrolizumab blocks PD-1 to restore anti-tumor immunity, while chemotherapy drugs kill cancer cells directly; together they enhance immune activation against residual disease. Used for Advanced or metastatic non-small cell lung cancer (NSCLC), Triple-negative breast cancer, Gastric or gastroesophageal junction cancer.
At a glance
| Generic name | Pembrolizumab and Chemotherapy drugs |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | PD-1 inhibitor (in combination with chemotherapy) |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pembrolizumab is a PD-1 inhibitor that removes the brake on T-cell-mediated anti-tumor immunity. Chemotherapy drugs induce immunogenic cell death and increase tumor antigen presentation. The combination leverages chemotherapy's cytotoxic effects with pembrolizumab's immune checkpoint blockade to improve overall anti-tumor response.
Approved indications
- Advanced or metastatic non-small cell lung cancer (NSCLC)
- Triple-negative breast cancer
- Gastric or gastroesophageal junction cancer
- Cervical cancer
Common side effects
- Fatigue
- Nausea
- Anemia
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Neutropenia
- Diarrhea
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pembrolizumab and Chemotherapy drugs CI brief — competitive landscape report
- Pembrolizumab and Chemotherapy drugs updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI
Frequently asked questions about Pembrolizumab and Chemotherapy drugs
What is Pembrolizumab and Chemotherapy drugs?
How does Pembrolizumab and Chemotherapy drugs work?
What is Pembrolizumab and Chemotherapy drugs used for?
Who makes Pembrolizumab and Chemotherapy drugs?
What drug class is Pembrolizumab and Chemotherapy drugs in?
What development phase is Pembrolizumab and Chemotherapy drugs in?
What are the side effects of Pembrolizumab and Chemotherapy drugs?
What does Pembrolizumab and Chemotherapy drugs target?
Related
- Drug class: All PD-1 inhibitor (in combination with chemotherapy) drugs
- Target: All drugs targeting PD-1
- Manufacturer: University Hospital, Brest — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer (NSCLC)
- Indication: Drugs for Triple-negative breast cancer
- Indication: Drugs for Gastric or gastroesophageal junction cancer
- Compare: Pembrolizumab and Chemotherapy drugs vs similar drugs
- Pricing: Pembrolizumab and Chemotherapy drugs cost, discount & access